Chiara Bortolasci

List of Publications by Year
in descending order

53	1,213	394421	414414
papers	citations	19 h-index	32 g-index

54	54	54	2131
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Oxidative stress and lowered total antioxidant status are associated with a history of suicide attempts. Journal of Affective Disorders, 2013, 150, 923-930.	4.1	101
2	Highly specific changes in antioxidant levels and lipid peroxidation in Parkinsonâ€™s disease and its progression: Disease and staging biomarkers and new drug targets. Neuroscience Letters, 2016, 617, 66-71.	2.1	91
3	Oxidative stress and inflammatory markers are associated with depression and nicotine dependence. Neuroscience Letters, 2013, 544, 136-140.	2.1	87
4	The pathophysiology of SARS-CoV-2: A suggested model and therapeutic approach. Life Sciences, 2020, 258, 118166.	4.3	79
5	Shared pathways for neuroprogression and somatoprogression in neuropsychiatric disorders. Neuroscience and Biobehavioral Reviews, 2019, 107, 862-882.	6.1	74
6	Lowered plasma paraoxonase (PON)1 activity is a trait marker of major depression and PON1 Q192R gene polymorphismâ€“smoking interactions differentially predict the odds of major depression and bipolar disorder. Journal of Affective Disorders, 2014, 159, 23-30.	4.1	68
7	The cytokine storms of COVID-19, H1N1 influenza, CRS and MAS compared. Can one sized treatment fit all?. Cytokine, 2021, 144, 155593.	3.2	61
8	Oxidative and nitrosative stress biomarkers in chronic schizophrenia. Psychiatry Research, 2017, 253, 43-48.	3.3	43
9	Trace Amine-Associated Receptor 1 (TAAR1): A new drug target for psychiatry?. Neuroscience and Biobehavioral Reviews, 2021, 120, 537-541.	6.1	42
10	Preventing the development of severe COVID-19 by modifying immunothrombosis. Life Sciences, 2021, 264, 118617.	4.3	40
11	A review of the neurobiological underpinning of comorbid substance use and mood disorders. Journal of Affective Disorders, 2018, 241, 388-401.	4.1	33
12	The role of high-density lipoprotein cholesterol, apolipoprotein A and paraoxonase-1 in the pathophysiology of neuroprogressive disorders. Neuroscience and Biobehavioral Reviews, 2021, 125, 244-263.	6.1	29
13	Factors influencing insulin resistance in relation to atherogenicity in mood disorders, the metabolic syndrome and tobacco use disorder. Journal of Affective Disorders, 2015, 179, 148-155.	4.1	27
14	The use of a gene expression signature and connectivity map to repurpose drugs for bipolar disorder. World Journal of Biological Psychiatry, 2020, 21, 775-783.	2.6	27
15	Adjunctive N-acetylcysteine in depression: exploration of interleukin-6, C-reactive protein and brain-derived neurotrophic factor. Acta Neuropsychiatrica, 2017, 29, 337-346.	2.1	25
16	Parkinson's Disease is Accompanied by Intertwined Alterations in Iron Metabolism and Activated Immune-inflammatory and Oxidative Stress Pathways. CNS and Neurological Disorders - Drug Targets, 2017, 16, 484-491.	1.4	25
17	The endocannabinoidome in neuropsychiatry: Opportunities and potential risks. Pharmacological Research, 2021, 170, 105729.	7.1	24
18	Systemic inflammation and grey matter volume in schizophrenia and bipolar disorder: Moderation by childhood trauma severity. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 105, 110013.	4.8	23

#	Article	IF	Citations
19	Association between childhood trauma exposure and pro-inflammatory cytokines in schizophrenia and bipolar-I disorder. Psychological Medicine, 2019, 49, 2736-2744.	4.5	22
20	Mechanisms Underpinning the Polypharmacy Effects of Medications in Psychiatry. International Journal of Neuropsychopharmacology, 2018, 21, 582-591.	2.1	19
21	The compensatory antioxidant response system with a focus on neuroprogressive disorders. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2019, 95, 109708.	4.8	19
22	Polyphenols as adjunctive treatments in psychiatric and neurodegenerative disorders: Efficacy, mechanisms of action, and factors influencing inter-individual response. Free Radical Biology and Medicine, 2021, 172, 101-122.	2.9	19
23	Inflammation and Nitro-oxidative Stress as Drivers of Endocannabinoid System Aberrations in Mood Disorders and Schizophrenia. Molecular Neurobiology, 2022, 59, 3485-3503.	4.0	19
24	Mediator effects of parameters of inflammation and neurogenesis from a N-acetyl cysteine clinical-trial for bipolar depression. Acta Neuropsychiatrica, 2018, 30, 334-341.	2.1	16
25	The Therapeutic Potential of Mangosteen Pericarp as an Adjunctive Therapy for Bipolar Disorder and Schizophrenia. Frontiers in Psychiatry, 2019, 10, 115.	2.6	16
26	Drugs used to treat bipolar disorder act via microRNAs to regulate expression of genes involved in neurite outgrowth. Journal of Psychopharmacology, 2020, 34, 370-379.	4.0	15
27	Association of paraoxonase (PON)1 activity, glutathione S-transferase GST T1/M1 and STin.2 polymorphisms with comorbidity of tobacco use disorder and mood disorders. Neuroscience Letters, 2015, 585, 132-137.	2.1	14
28	Are PTH levels related to oxidative stress and inflammation in chronic kidney disease patients on hemodialysis?. Jornal Brasileiro De Nefrologia: Orgao Oficial De Sociedades Brasileira E Latino-Americana De Nefrologia, 2016, 38, 288-295.	0.9	13
29	Can endolysosomal deacidification and inhibition of autophagy prevent severe COVID-19?. Life Sciences, 2020, 262, 118541.	4.3	12
30	Cognition-immune interactions between executive function and working memory, tumour necrosis factor-alpha (TNF-alpha) and soluble TNF receptors (sTNFR1 and sTNFR2) in bipolar disorder. World Journal of Biological Psychiatry, 2022, 23, 67-77.	2.6	11
31	Transcriptional Modulation of the Hippo Signaling Pathway by Drugs Used to Treat Bipolar Disorder and Schizophrenia. International Journal of Molecular Sciences, 2021, 22, 7164.	4.1	11
32	N-acetylcysteine for cessation of tobacco smoking: rationale and study protocol for a randomised controlled trial. Trials, 2019, 20, 555.	1.6	8
33	Total Antioxidant Capacity and Frailty in Older Men. American Journal of Men's Health, 2020, 14, 155798832094659.	1.6	8
34	Biological Mechanism(s) Underpinning the Association between Antipsychotic Drugs and Weight Gain. Journal of Clinical Medicine, 2021, 10, 4095.	2.4	8
35	Effects of Psychotropic Drugs on Ribosomal Genes and Protein Synthesis. International Journal of Molecular Sciences, 2022, 23, 7180.	4.1	8
36	Paraoxonase (PON)1 Q192R functional genotypes and PON1 Q192R genotype by smoking interactions are risk factors for the metabolic syndrome, but not overweight or obesity. Redox Report, 2014, 19, 232-241.	4.5	7

#	Article	IF	Citations
37	Transcriptional Effects of Psychoactive Drugs on Genes Involved in Neurogenesis. International Journal of Molecular Sciences, 2020, 21, 8333.	4.1	7
38	Association between serum interleukin-6 and frailty in older men: cross-sectional data. European Geriatric Medicine, 2021, 12, 887-892.	2.8	7
39	Co-Expression Networks Unveiled Long Non-Coding RNAs as Molecular Targets of Drugs Used to Treat Bipolar Disorder. Frontiers in Pharmacology, 2022, 13, 873271.	3.5	7
40	Exploring interleukin-6, lipopolysaccharide-binding protein and brain-derived neurotrophic factor following 12 weeks of adjunctive minocycline treatment for depression. Acta Neuropsychiatrica, 2022, 34, 220-227.	2.1	7
41	Paraoxonase 1 status and interactions between Q192R functional genotypes by smoking contribute significantly to total plasma radical trapping antioxidant potential. Neuroscience Letters, 2014, 581, 46-51.	2.1	6
42	Intertwined associations between oxidative and nitrosative stress and endocannabinoid system pathways: Relevance for neuropsychiatric disorders. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2022, 114, 110481.	4.8	6
43	Increased oxidative stress in foam cells obtained from hemodialysis patients. Hemodialysis International, 2013, 17, 266-274.	0.9	5
44	Drugs used in the treatment of bipolar disorder and their effects on cholesterol biosynthesis â€“ A possible therapeutic mechanism. World Journal of Biological Psychiatry, 2019, 20, 766-777.	2.6	5
45	Effects of psychoactive drugs on cellular bioenergetic pathways. World Journal of Biological Psychiatry, 2021, 22, 79-93.	2.6	5
46	Passiflora incarnata treatment during gestation and lactation: toxicological and antioxidant evaluation in wistar dams. Brazilian Journal of Pharmaceutical Sciences, 2014, 50, 353-359.	1.2	3
47	Interleukin-6 and total antioxidant capacity levels following N-acetylcysteine and a combination nutraceutical intervention in a randomised controlled trial for bipolar disorder. Acta Neuropsychiatrica, 2020, 32, 313-320.	2.1	3
48	Common effects of bipolar disorder medications on expression quantitative trait loci genes. Journal of Psychiatric Research, 2022, 150, 105-112.	3.1	2
49	Integrative Analyses of Transcriptomes to Explore Common Molecular Effects of Antipsychotic Drugs. International Journal of Molecular Sciences, 2022, 23, 7508.	4.1	2
50	First-Episode Schizophrenia and Diabetes Risk. JAMA Psychiatry, 2017, 74, 761.	11.0	1
51	Minocycline for the treatment of mental health and neurological conditions: study protocol of a systematic review and meta-analysis. BMJ Open, 2020, 10, e035080.	1.9	1
52	Baseline serum amino acid levels predict treatment response to augmentation with N-acetylcysteine (NAC) in a bipolar disorder randomised trial. Journal of Psychiatric Research, 2021, 142, 376-383.	3.1	1
53	A placebo-controlled, randomised pilot trial of N-acetylcysteine or placebo for cessation of tobacco smoking. European Neuropsychopharmacology, 2021, 53, 120-126.	0.7	0